Monte Rosa治疗学合作伙伴与Novartis在一项2B交易中与Novartis合作,进行自发免疫疾病药物开发。 Monte Rosa Therapeutics partners with Novartis in a $2B deal for autoimmune disease drug development.

Monte Rosa治疗技术公司与Novartis合作,一项价值可能超过20亿美元的交易,开发分子胶液降解器,包括MRT-6160,旨在治疗自发免疫疾病。 Monte Rosa Therapeutics has partnered with Novartis in a deal potentially worth over $2 billion to develop molecular glue degraders, including MRT-6160, aimed at treating autoimmune diseases. Novartis将提前支付1.5亿美元,并视药物的成功情况,可提供额外的里程碑付款。 Novartis will pay $150 million upfront and could provide additional milestone payments contingent on the drug's success. 虽然诺华公司将处理第二阶段以后的开发工作,但蒙特罗萨公司将继续其正在进行的第一阶段试验,并分担美国的利润和损失。 While Novartis will handle development from Phase 2 onward, Monte Rosa will continue its ongoing Phase 1 trial and share in U.S. profits and losses.